iSpecimen Inc. operates marketplace that provides biospecimens to life science researchers in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. The company's marketplace offers human biospecimens, including biofluids, such as whole blood, plasma, serum, urine, saliva, sputum, nasopharyngeal material, and cerebral spinal fluid; solid tissue comprising fresh, fixed, and cryopreserved tissue, as well as formalin-fixed paraffin embedded blocks, slides, and curls; and hematopoietic stem and immune cells, including bone marrow, cord blood, whole blood, or sub-components of these tissues, such as peripheral blood mononuclear cells and other isolated cell types. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. iSpecimen Inc. was incorporated in 2009 and is headquartered in Woburn, Massachusetts.…
iSpecimen Reports 129% Year-Over-Year Increase in Third Quarter Revenue; Highlights Completed Orders for Federal Government and the Centers for Disease Control and Prevention (CDC)
iSpecimen (NASDAQ: ISPC) is listed on Nasdaq, where its shares trade in USD. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 7 employees.
The shares were at 0.4563 USD on 20 November 2026, down 98.2% over 52 weeks. Its 52-week range is 0.4323 USD to 27.44 USD: the price is 98.3% below the high and 5.6% above the low.
Its market capitalisation is 2.64M USD.
iSpecimen reports return on equity of -339.6% and revenue up 128.9% year over year.
It holds more cash than debt, a net cash position of 5.33M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.